Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia.

Purpose: Rituximab/chemotherapy is a cornerstone of treatment for Waldenström's macroglobulinemia (WM). In addition, bortezomib has shown significant activity in WM. This study evaluated the efficacy and safety of dexamethasone, rituximab, and cyclophosphamide (DRC) as first-line treatment in WM.

Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?

In symptomatic Waldenström macroglobulinemia (sWM) patients, prognosis is assessed with the international prognostic scoring system (IPSSWM). In follicular lymphoma and other B-cell and T-cell lymphomas, disease progression within 24 months (POD24) or (in patients without POD24) after 24 months has been proposed as the start date for stratifying subsequent survival. In the present report, we assessed in a large series of 472 sWM patients, the prognostic value of this new dynamic endpoint already reported in many other lymphomas subtypes.

Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.

Few reports assess prognosis during follow-up of patients with symptomatic Waldenström macroglobulinemia (WM). In 121 WM patients treated between 1993 and 2016, we analyzed the prognostic role during the clinical course of the initial International Prognostic Scoring System for WM (IPSSWM). Then, we assessed onset of response, progression, and second treatment initiation coded as time-dependent covariates.

A phase II Bayesian sequential clinical trial in advanced Waldenström macroglobulinemia patients treated with bortezomib: interest of addition of dexamethasone.

In patients with advanced Waldenström macroglobulinemia (WM), overall response rate (ORR) and median progression-free survival (PFS) achieved with bortezomib alone and bortezomib rituximab combination were 27-85% and 7.9 months, and 81% and 16.4 months, respectively.

BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years.

In this phase 2 multicenter trial, we evaluated the efficacy of the combination of bortezomib, dexamethasone, and rituximab (BDR) in 59 previously untreated symptomatic patients with Waldenström macroglobulinemia (WM), most of which were of advanced age and with adverse prognostic factors. BDR consisted of a single 21-day cycle of bortezomib alone (1.3 mg/m IV on days 1, 4, 8, and 11), followed by weekly IV bortezomib (1.

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia.

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of the International Workshop on Waldenström's Macroglobulinemia (IWWM). At IWWM-8, a task force for treatment recommendations was impanelled to review recently published and ongoing clinical trial data as well as the impact of new mutations (MYD88 and CXCR4) on treatment decisions, indications for B-cell receptor and proteasome inhibitors, and future clinical trial initiatives for WM patients. The panel concluded that therapeutic strategies in WM should be based on individual patient and disease characteristics.

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Waldenström macroglobulinemia (WM) is a distinct B-cell lymphoproliferative disorder for which clearly defined criteria for the diagnosis, initiation of therapy, and treatment strategy have been proposed as part of the consensus panels of International Workshops on WM (IWWM). As part of the IWWM-7 and based on recently published and ongoing clinical trials, the panels updated treatment recommendations. Therapeutic strategy in WM should be based on individual patient and disease characteristics (age, comorbidities, need for rapid disease control, candidacy for autologous transplantation, cytopenias, IgM-related complications, hyperviscosity, and neuropathy).

Can ISSWM be used for making treatment decisions?

Using age, hemoglobin level, platelet count, serum β2-microglobulin and monoclonal protein concentrations, the International Scoring System for WM (ISSWM) has been specifically designed for predicting survival after the initiation of first-line therapy. Five-year survival rates of low-, intermediate-, and high-risk patients were 87%, 68%, and 36%, respectively. The aim of the present review was to assess the applicability of this statistical model for making treatment decision in clinical practice, despite the difficulties posed by the characteristics of this rare disease.

Comparison of two high-dose cyclophosphamide, doxorubicin, vincristine, and prednisone derived regimens in patients aged under 60 years with low-intermediate risk aggressive lymphoma: a final analysis of the multicenter LNH93-2 protocol.

One-third of patients aged View Article and Find Full Text PDF

Prognostic factors in Waldenstrom's macroglobulinemia: description of the complications during the evolution-preliminary results on 101 patients.

Data on clinical features observed in patients with Waldenstrom's macroglobulinemia (WM) during follow-up remain limited. Therefore, we evaluated 860 follow-up procedures in 101 patients. Median age was 66 years and 5-year overall survival 72%, with a median follow-up of 36 months in surviving patients.

Assessing the Cox model assumption as a statistical tool for classifying lymphomas.

Introduction: The Cox model is widely used in medical research for comparing survival. Lymphomas might exhibit important differences in long-term cure rate despite a similar survival.

Methods: Using log-rank test, we compared event-free survival (EFS), and the survival of 64 patients with mantle cell lymphoma (MCL), 525 patients with follicular lymphoma, and 1136 patients with diffuse centroblastic lymphoma (CB).

[Five years survival after treatment of gallbladder metastasis of malignant melanoma].

A case of an isolated gallbladder metastasis from a malignant melanoma is reported in a 32 year old woman. The patient has been treated by cholecystectomy and chemotherapy and was free of any recurrence 5 years after treatment.

[Primary non-parasitic cyst of the diaphragm. Review of the literature. Apropos of a case].

The authors report a case of mesothelial cyst of the diaphragm, discovered on ultrasonography performed for pain in the right hypochondrium and treated by simple surgical excision. Based on a review of the literature, they define the topographical, histological and therapeutic aspects of these lesions, which are now recognised more frequently due to the progress in medical imaging.

[Cephalic duodenopancreatectomy with preservation of the pylorus].

We report a technique of cephalic pancreatico-duodenectomy preserving the pylorus which differs from that initially devised by Longmire and Traverso. Restoration of digestive tract continuity consists successively of end-to-end duodeno-jejunal anastomosis, end-to-side choledoco-jejunal anastomosis and end-to-side pancreatico-jejunal anastomosis. The simple technique has the advantage of restoring a perfectly physiological circuit.